US to put up $2.1 bn for Sanofi, GSK coronavirus vaccine
Sanofi, based in France, and GSK of Britain said clinical trials with their vaccine should start in September, with a Phase 3 study under way by the end of the year.
Paris: Pharma giants Sanofi and GSK will receive up to $2.1 billion from the US government for the development of a COVID-19 vaccine, the companies said Friday, as the world reels from the coronavirus epidemic.
The United States has identified a vaccine candidate under development by Sanofi and GSK for its "Operation Warp Speed," which aims to rapidly secure millions of doses.
The firms aim to combine a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine.
The American money, they said in a statement, will "help fund the development activities and secure scale-up of Sanofi's and GSK's manufacturing capabilities in the United States... resulting in a significant increase in capacity."
"The US government will provide up to $2.1 billion, more than half of which is to support further development of the vaccine, including clinical trials, with the remainder used for manufacturing scale-up and delivery of an initial 100 million doses," they said.
"The US government has a further option for the supply of an additional 500 million doses longer term," they added.
The United States is the country the worst hit by the coronavirus outbreak, with over 150,000 deaths out of the global toll of more than 667,000.
Sanofi, based in France, and GSK of Britain said clinical trials with their vaccine should start in September, with a Phase 3 study under way by the end of the year.
- Billion doses per year - "If the data are positive, the companies can request US regulatory approval in the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year globally," they said.
US Health and Human Services Secretary Alex Azar said the portfolio of vaccines being assembled under Operation Warp Speed "increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year."
The United States has already committed some $6 billion since March to vaccine projects with pharma giants such as Johnson & Johnson, Pfizer and AstraZeneca.
The latest investment holds the "potential to bring hundreds of millions of safe and effective doses to the American people," Azar said in the statement.
The companies said discussions were also under way with the European Commission and other governments "to ensure global access to a novel coronavirus vaccine."
The partners intended to supply "a significant portion of total worldwide available supply capacity" in 2021 and 2022 to an initiative seeking to ensure equitable global access to COVID-19 tests, treatments and vaccines.
'Global public good' - Sanofi CEO Paul Hudson drew the ire of French officials in May when he suggested any COVID-19 vaccine would be offered first to the US government because it had been investing in its development.
Under pressure, he later indicated it would be available to everyone at the same time.
Other countries too, have been investing in a vaccine against the novel coronavirus, with Sanofi and GSK announcing a deal with Britain on Wednesday for 60 million doses, and hoping for an agreement with the European Union shortly for another 300 million doses.
Laboratories need the money to accelerate the early stages of vaccine development and prepare production units without fearing they will be left out of pocket if the candidate drugs fail.
In turn, governments seek to ensure they will get the first doses if the vaccines do work.
But such deals have drawn criticism for leaving behind poor countries who do not have the cash to conclude any such contracts.
Earlier this month, the UN Human Rights Council stressed the importance of "equitable and unhindered access" to diagnostics, treatments and vaccines, and said any vaccine developed against COVID-19 should be considered a "global public good".
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.